ScholarIQanswers from OpenAlex & ORCID
Mabel Ryder
ResearcherPublications, citations & collaboration network
Mabel Ryder is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Mabel Ryder have?
ScholarIQindexed works
Mabel Ryder has 167 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Mabel Ryder have?
ScholarIQcitation count
Mabel Ryder has 6,015 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Mabel Ryder?
ScholarIQh-index
Mabel Ryder has an h-index of 30 in OpenAlex.
What is the i10-index of Mabel Ryder?
ScholarIQi10-index
Mabel Ryder has an i10-index of 49 in OpenAlex.
What is the ORCID of Mabel Ryder?
ScholarIQorcid
The ORCID for Mabel Ryder is on the source record.
What is the OpenAlex record for Mabel Ryder?
ScholarIQopenalex
The OpenAlex for Mabel Ryder is on the source record.
What are the most-cited papers on Mabel Ryder?
ScholarIQmost cited works
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone
Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF, PIK3CA</i> , and <i>AKT1</i>
Julio C. Ricarte‐Filho, Mabel Ryder, Dhananjay Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David B. Solit, Jeffrey A. Knauf, R. Michael Tuttle, Ronald Ghossein, James A. Fagin
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Benjamin H. Kaffenberger, Matthew A. Lunning, Suzanne McGettigan, Jordan P. McPherson, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Nathan A. Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, Anita M. Engh
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Mabel Ryder, Margaret K. Callahan, Michael A. Postow, Jedd D. Wolchok, James A. Fagin
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Amaka Achufusi, Philippe Armand, Meghan Berkenstock, Shailender Bhatia, Lihua E. Budde, Saurin Chokshi, Marianne Davies, Amro Elshoury, Yaron Gesthalter, Aparna Hegde, Michael D. Jain, Benjamin H. Kaffenberger, Melissa G. Lechner, Tianhong Li, Alissa Marr, Suzanne McGettigan, Jordan P. McPherson, Theresa Medina, Nisha Mohindra, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Pradnya D. Patil, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Vlad G. Zaha, Megan Lyons, Mary A. Dwyer, Lisa Hang